Global Immunology Market to Reach $74.2 Billion By 2022

Feb 10, 2016, 10:30 ET from MarketIntelReports

WELMINGTON, Delaware, February 10, 2016 /PRNewswire/ --

The complexity of the immune system has led to some intrinsic obstacles with clinical research, particularly in relation to targeting the right genes, identifying the appropriate patient population and accessing internal tissues for testing. Market access presents a significant hurdle for immunotherapeutic procedures, as many are high cost and do not deliver the measurements required for traditional cost-effectiveness assessments. Despite these restraining factors, The Global Immunology Market is expected to experience continued growth, from $61.5 Billion in 2015 to $74.2 Billion in 2022, at 2.71% CAGR.

Complete research on Global Immunology Market to 2022 available at

According to a recent study, the infections caused by rotavirus every year across the world is around 111 million; with approximately 2 million hospitalizations and 400,000 deaths of children under 5 years old alone. The under developed and developing countries such as Asia, Africa and some more are the biggest target regions for the earlier mentioned statistics. Around 82% of the total cases are registered from the children in Asia and Africa.

Also, the dangerous HBV affected almost 1.4 million of the US population in 2011 and has been acting as major public health challenge ever since. The swine flu virus, zika virus, in the latest records plus additional infections has deteriorated the situation in the past few years (with zika spreading currently). All these outbursts will lead to the growth and strengthening of the Immunology Market during the coming few years.

Data Summary:  

Immune-mediated inflammatory diseases are a very common set of chronic disorders that affect 5% - 7% of western populations. Although they are often disparate in terms of their symptoms and key patient demographics, they are pathophysiologically linked, being characterized by deregulation of immune pathways and an inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, a highly generalized class of systemic small-molecule-based agents, are used in the first-line treatment of these diseases. These are supplemented in many cases by shorter-term glucocorticoid therapy, another class of highly generalized systemic agents.

However, as these therapies often fail to elicit an adequate long-term response, a large second-line therapy segment has emerged in Immunology markets, beginning with the approval of Remicade (infliximab) and Enbrel (etanercept) in 1998. This segment consists largely of premium systemic monoclonal Antibodies (mAbs), which are highly commercially successful due to their widespread usage and high cost. The patents for many of these mAbs either have already expired or are due to expire during the forecast period, contributing further to the growth of the immunology market and penetration across geographic regions.

Request Research Sample here

Prominent Top Competitors: 

Apart from the market segmentation, Key Market Insights on the Past, Future & Present of the Immunology Market, this report includes an in-depth analysis and study on the Key Players at a Global Scale.

AbbVie, Johnson & Johnson, Amgen, Genentech/ Roche, Astellas, UCB, Eli Lilly, Sanofi, Astra Zeneca, Novartis and many more key players of Immunology Market are mentioned in this report on Immunology Market. The key players in the market, all of which are among the top 20 pharmaceutical companies, are expected to maintain their market lead throughout the forecast period 2015-2022.

Order a Copy of Global Immunology Market to 2022 report @

Immunology Market Research will allow you to -  

  • Visualize the composition of the immunology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players.
  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis.
  • Analyze the immunology pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications.
  • Understand the growth in patient epidemiology and market revenues for the immunology market globally and across the key players and product types.
  • Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various immunological disorders.

Related Reports 

On a related note, another research on COPD Therapeutics in Major Developed Markets to 2021 forecast to rise from a value of $9.2 Billion in 2014 to $11.2 Billion in 2021, at a CAGR of 2.9% across the Eight Major Markets. Assessed research report available at

About MarketIntelReports: 

MarketIntelReports (MIR) aims to empower our clients to successfully manage and outperform in their business decisions. We do this by providing Premium Market Intelligence, Strategic Insights and Databases from a range of Global Publishers.

MarketIntelReports currently has more than 10,000 plus titles and 35+ Publishers on our platform and growing consistently to fill the "Global Intelligence Demand - Supply Gap". We cover more than 15 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Building & Construction, Agriculture, Food & Beverages, Banking & Finance, Media and Government, Public Sector Studies.

Media Contact
Mr. Mayur S.
Sales Manager
Telephone: 1-302-684-6088
2711 Centerville Road, Suite 400,
Wilmington, Delaware, 19808
United States

SOURCE MarketIntelReports